Polomar Health Services is a small, early-stage compounding pharmacy based in Palm Harbor, FL that compounds and dispenses prescription drugs to patients across 28 states, primarily through online telehealth channels. Through its subsidiary Polomar Specialty Pharmacy, the company has shifted its focus from topical dermatological medications toward compounded injectable GLP-1 weight loss drugs (semaglutide and tirzepatide) and erectile dysfunction medications (sildenafil). Polomar operates two business lines: a wholesale fulfillment model, where it acts as the back-end pharmacy for third-party telehealth platforms (primarily CareValidate), and a direct-to-consumer platform called SlimRx, planned for Q2 2026 launch, which would connect patients directly with licensed providers and funnel prescriptions to Polomar, bypassing third-party intermediaries. Polomar does not accept insurance; all revenue is direct pay. The company manufactures sterile injectables in-house at its Florida facility and sources non-sterile compounded drugs from FDA-approved third-party outsourcing facilities. Polomar also holds patent-pending IP for novel drug delivery formats, including inhalable sildenafil (branded VigorAir), inhalable eletriptan, and a metformin gummy, though none have generated meaningful revenue. The business carries a royalty obligation of 10-20% of net sales on products using licensed IP. A pending merger with Altanine would result in Altanine shareholders owning roughly 80% of the combined entity.